Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Immunol., 24 July 2025

Sec. Multiple Sclerosis and Neuroimmunology

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1652299

Correction: The P2X7R-antagonist AFC-5128 ameliorates chronic experimental autoimmune encephalomyelitis in a preventive and therapeutic paradigm

  • 1Department of Neurology, St. Josef-Hospital, Bochum, Germany
  • 2Translational Neurology Group, Department of Clinical Science, Lund University, Lund, Sweden
  • 3Molecular Cell Biology, Ruhr-University, Bochum, Germany
  • 4Affectis Pharmaceuticals AG, Dortmund, Germany
  • 5KHAN Technology Transfer Fund I GmbH & Co KG, Dortmund, Germany
  • 6Lead Discovery Center GmbH, Dortmund, Germany
  • 7Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gemeinnützige GmbH, Berg, Germany

A Correction on
The P2X7R-antagonist AFC-5128 ameliorates chronic experimental autoimmune encephalomyelitis in a preventive and therapeutic paradigm

By Hoffrogge R, Karachunskaya A, Heitmann N, Pedreiturria X, Klöster K, Bader V, Winklhofer KF, Hamacher M, Klebl B, Gold R, Dinkel K, Kleiter I and Faissner S (2025). Front. Immunol. 16:1554999. doi: 10.3389/fimmu.2025.1554999

Author “Steffen Haupeltshofer” was omitted as an author in the published article. The correct author list reads:

“Robert Hoffrogge1, Anna Karachunskaya1, Neele Heitmann1, Steffen Haupeltshofer2, Xiomara Pedreiturria1, Katharina Klöster1, Verian Bader3, Konstanze F. Winklhofer3, Michael Hamacher4, Bert Klebl5, Ralf Gold1, Klaus Dinkel6, Ingo Kleiter1,7, Simon Faissner1*

1Department of Neurology, St. Josef-Hospital, Bochum, Germany

2Translational Neurology Group, Department of Clinical Science, Lund University, Lund, Sweden

3Molecular Cell Biology, Ruhr-University, Bochum, Germany

4Affectis Pharmaceuticals AG, Dortmund, Germany

5KHAN Technology Transfer Fund I GmbH & Co KG, Dortmund, Germany

6Lead Discovery Center GmbH, Dortmund, Germany

7Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gemeinnützige GmbH, Berg, Germany”

The Author contributions statement has been corrected to read:

“RH: Writing – original draft, Writing – review & editing, Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Visualization. AK: Writing – review & editing, Formal Analysis, Investigation, Methodology, Visualization. NH: Writing – review & editing, Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Validation, Visualization. SH: Writing – original draft, Writing – review & editing, Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Validation, Visualization.XP: Writing – review & editing, Formal Analysis, Investigation, Methodology, Project administration, Resources, Validation. KK: Writing – review & editing, Data curation, Formal Analysis, Investigation, Methodology. VB: Writing – review & editing, Formal Analysis, Investigation, Methodology, Software, Visualization. KW: Writing – review & editing, Formal Analysis, Methodology, Resources, Software. MH: Writing – review & editing, Resources. BK: Writing – review & editing, Resources. RG: Writing – review & editing, Funding acquisition, Resources. KD: Writing – review & editing, Resources. IK: Writing – review & editing, Conceptualization, Formal Analysis, Funding acquisition, Supervision, Visualization. SF: Writing – original draft, Writing – review & editing, Conceptualization, Data curation, Formal Analysis, Funding acquisition, Methodology, Project administration, Resources, Supervision, Validation, Visualization.”

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: P2X7R, progressive multiple sclerosis, microglia, neuroinflammation, neuroprotection

Citation: Hoffrogge R, Karachunskaya A, Heitmann N, Haupeltshofer S, Pedreiturria X, Klöster K, Bader V, Winklhofer KF, Hamacher M, Klebl B, Gold R, Dinkel K, Kleiter I and Faissner S (2025) Correction: The P2X7R-antagonist AFC-5128 ameliorates chronic experimental autoimmune encephalomyelitis in a preventive and therapeutic paradigm. Front. Immunol. 16:1652299. doi: 10.3389/fimmu.2025.1652299

Received: 23 June 2025; Accepted: 09 July 2025;
Published: 24 July 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Hoffrogge, Karachunskaya, Heitmann, Haupeltshofer, Pedreiturria, Klöster, Bader, Winklhofer, Hamacher, Klebl, Gold, Dinkel, Kleiter and Faissner. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Simon Faissner, c2ltb24uZmFpc3NuZXJAcnViLmRl

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.